EUVIMEDEUVIMED entdecken
Crossref

Will Continuous Glucose Monitoring Metrics Replace Hemoglobin A1c in Assessing the Risk of Retinopathy (and Other Complications) in Patients with Type 2 Diabetes?

Magdalena Walicka, Edward Franek

Clinical Diabetology · 2024

DOI: 10.5603/cd.101353 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Diabetology, 2024. Verfasst von Magdalena Walicka und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Walicka, M., & Franek, E. (2024). Will Continuous Glucose Monitoring Metrics Replace Hemoglobin A1c in Assessing the Risk of Retinopathy (and Other Complications) in Patients with Type 2 Diabetes?. Clinical Diabetology. https://doi.org/10.5603/cd.101353

Vancouver

Walicka M, Franek E. Will Continuous Glucose Monitoring Metrics Replace Hemoglobin A1c in Assessing the Risk of Retinopathy (and Other Complications) in Patients with Type 2 Diabetes?. Clinical Diabetology. 2024. doi:10.5603/cd.101353

BibTeX
@article{Walicka2024,
  author = {Walicka, Magdalena and Franek, Edward},
  title = {Will Continuous Glucose Monitoring Metrics Replace Hemoglobin A1c in Assessing the Risk of Retinopathy (and Other Complications) in Patients with Type 2 Diabetes?},
  journal = {Clinical Diabetology},
  year = {2024},
  doi = {10.5603/cd.101353}
}
Kostenlos starten →